3D Medicines Inc. (1244.HK)
HKD 3.34
(-1.47%)
HKD 3.34
(-1.47%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -497.24 Million CNY | 51.87% |
| 2022 | -996.46 Million CNY | 31.67% |
| 2021 | -1.45 Billion CNY | -132.42% |
| 2020 | -627.47 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -35.15 Million CNY | 79.08% |
| 2024 Q2 | -35.15 Million CNY | 0.0% |
| 2023 Q2 | -104.88 Million CNY | 0.0% |
| 2023 FY | -479.63 Million CNY | 51.87% |
| 2023 Q3 | -143.74 Million CNY | -37.05% |
| 2023 Q1 | -104.88 Million CNY | -15.6% |
| 2023 Q4 | -168.09 Million CNY | -16.94% |
| 2022 FY | -996.46 Million CNY | 31.67% |
| 2022 Q3 | -90.72 Million CNY | 0.0% |
| 2022 Q4 | -90.72 Million CNY | 0.0% |
| 2021 FY | -1.45 Billion CNY | -132.42% |
| 2020 FY | -627.47 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | 833.749% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 155.376% |